Profile data is unavailable for this security.
About the company
Palatin Technologies, Inc. is a biopharmaceutical company. The Company is engaged in developing medicines based on molecules that modulate the activity of the melanocortin receptor systems, with targeted, receptor-specific product candidates for the treatment of diseases with unmet medical need and commercial potential. Its new product development activities focus primarily on MC1r agonists, with potential to treat inflammatory and autoimmune diseases, such as dry eye disease, known as keratoconjunctivitis sicca, uveitis, diabetic retinopathy, and inflammatory bowel disease. It is also engaged developing peptides that are active at more than one melanocortin receptor, and MC4r peptide and small molecule agonists with potential utility in obesity and metabolic-related disorders, including rare disease and orphan indications. It has completed Phase III PL9643 clinical study for dry eye disease. It is also conducting Phase II study of oral PL8177 in patients with ulcerative colitis.
- Revenue in USD (TTM)5.90m
- Net income in USD-32.20m
- Incorporated1986
- Employees34.00
- LocationPalatin Technologies Inc4B Cedar Brook DriveCRANBURY 08512United StatesUSA
- Phone+1 (609) 495-2200
- Fax+1 (609) 495-2202
- Websitehttps://www.palatin.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| bioAffinity Technologies Inc | 4.94m | -8.37m | 28.68m | 75.00 | -- | 5.25 | -- | 5.81 | -0.9197 | -0.9197 | 0.5416 | 0.4687 | 0.5334 | 318.22 | 8.70 | 65,839.60 | -90.38 | -- | -104.93 | -- | 32.88 | -- | -169.42 | -- | 2.21 | -- | 0.1782 | -- | 52,660.42 | -- | 2.66 | -- | -- | -- |
| Raphael Pharmaceutical Inc | 0.00 | -1.57m | 28.74m | 0.00 | -- | -- | -- | -- | -0.0929 | -0.0929 | 0.00 | -0.0055 | 0.00 | -- | -- | -- | -624.25 | -- | -- | -- | -- | -- | -- | -- | -- | -173.44 | -- | -- | -- | -- | 61.76 | -- | -- | -- |
| Aspira Women's Health Inc | 8.99m | -14.74m | 29.01m | 64.00 | -- | -- | -- | 3.23 | -1.33 | -1.33 | 0.8698 | -0.1104 | 0.9637 | 13.76 | 5.83 | 140,484.40 | -158.00 | -110.58 | -395.41 | -151.88 | 58.84 | 45.23 | -163.95 | -334.08 | 1.11 | -- | 3.10 | -- | 11.85 | 24.56 | 44.15 | -- | -26.65 | -- |
| Bolt Biotherapeutics Inc | 11.32m | -63.03m | 29.53m | 100.00 | -- | 0.2835 | -- | 2.61 | -1.66 | -1.66 | 0.2987 | 2.73 | 0.0649 | -- | -- | 113,240.00 | -36.11 | -48.32 | -39.88 | -54.03 | -- | -- | -556.59 | -2,267.00 | -- | -- | 0.00 | -- | 37.48 | -- | 21.45 | -- | -6.61 | -- |
| Spruce Biosciences Inc | 10.13m | -46.75m | 29.86m | 22.00 | -- | 0.4482 | -- | 2.95 | -1.15 | -1.15 | 0.2483 | 1.62 | 0.0894 | -- | -- | 349,206.90 | -41.26 | -41.24 | -50.47 | -46.49 | -- | -- | -461.67 | -1,774.39 | -- | -114.54 | 0.0423 | -- | -- | -- | -3.77 | -- | -- | -- |
| Promis Neurosciences Inc | 0.00 | -11.89m | 31.85m | 6.00 | -- | 413.14 | -- | -- | -0.8292 | -0.8292 | 0.00 | 0.0041 | 0.00 | -- | -- | 0.00 | -298.08 | -144.28 | -- | -262.23 | -- | -- | -- | -2,271,047.00 | -- | -- | 0.00 | -- | -- | -- | 26.85 | -- | -- | -- |
| Palatin Technologies, Inc. | 5.90m | -32.20m | 32.11m | 34.00 | -- | 20.34 | -- | 5.44 | -2.39 | -2.39 | 0.4275 | 0.0979 | 0.3189 | 0.6402 | 6.95 | 173,588.80 | -173.98 | -26.11 | -387.23 | -30.68 | 96.58 | -- | -545.58 | -126.20 | 1.20 | -- | 0.0443 | -- | 230.53 | -40.87 | 23.91 | -- | 80.82 | -- |
| RenovoRx Inc | 0.00 | -8.05m | 32.33m | 8.00 | -- | 12.89 | -- | -- | -0.7249 | -0.7249 | 0.00 | 0.1048 | 0.00 | -- | -- | 0.00 | -172.23 | -- | -231.65 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -3.47 | -- | -- | -- |
| Goldenwell Biotech Inc | 2.34k | -116.90k | 32.42m | -- | -- | 382.70 | -- | 13,855.77 | -0.0012 | -0.0012 | 0.00002 | 0.0009 | 0.0098 | 0.0071 | -- | -- | -49.07 | -- | -52.16 | -- | 47.01 | -- | -4,995.73 | -- | 37.75 | -- | 0.00 | -- | -95.10 | -- | 88.13 | -- | -- | -- |
| IGC Pharma Inc | 1.22m | -14.15m | 32.61m | 61.00 | -- | 3.45 | -- | 26.81 | -0.2479 | -0.2479 | 0.0217 | 0.142 | 0.0776 | 0.2084 | 7.09 | 19,934.43 | -90.30 | -33.35 | -100.90 | -35.84 | 51.40 | 8.74 | -1,163.24 | -410.26 | 0.8564 | -- | 0.0153 | -- | 129.47 | -16.11 | 23.38 | -- | 25.28 | -- |
| Surrozen Inc | 0.00 | -37.58m | 32.92m | 42.00 | -- | 0.7194 | -- | -- | -18.44 | -18.44 | 0.00 | 14.30 | 0.00 | -- | -- | 0.00 | -67.75 | -- | -77.52 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -100.00 | -- | -19.55 | -- | -- | -- |
| LianBio - ADR | 0.00 | -87.98m | 34.24m | 163.00 | -- | 0.1678 | -- | -- | -0.8195 | -0.8195 | 0.00 | 1.89 | 0.00 | -- | -- | 0.00 | -28.62 | -- | -35.22 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 43.82 | -- | -- | -- |
| Lipocine Inc | 4.71m | -8.97m | 34.98m | 17.00 | -- | 1.45 | -- | 7.42 | -1.71 | -1.71 | 0.8889 | 4.51 | 0.1585 | -- | 67.70 | 277,138.80 | -30.16 | -39.32 | -32.00 | -45.87 | -- | -- | -190.35 | -442.26 | -- | -- | 0.00 | -- | -670.16 | -- | -51.99 | -- | -- | -- |
| Rapid Micro Biosystems Inc | 23.10m | -51.90m | 35.15m | 193.00 | -- | 0.3312 | -- | 1.52 | -1.20 | -1.20 | 0.5355 | 2.48 | 0.1535 | 1.37 | 4.34 | 119,663.20 | -34.49 | -- | -38.20 | -- | -22.59 | -- | -224.73 | -- | 5.62 | -- | 0.0028 | -- | 31.44 | -- | 13.71 | -- | -- | -- |
| Nuo Therapeutics Inc | 782.01k | -3.02m | 35.19m | -- | -- | 103.49 | -- | 44.99 | -0.071 | -0.071 | 0.0183 | 0.0075 | 0.4516 | 0.7856 | 4.30 | -- | -174.64 | -116.16 | -294.62 | -354.84 | 78.74 | 70.02 | -386.76 | -854.53 | 1.01 | -1,418.93 | 0.00 | -- | 442.12 | -14.99 | 0.0095 | -- | -- | -- |
Data as of May 24 2024. Currency figures normalised to Palatin Technologies Inc's reporting currency: US Dollar USD
7.23%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Mar 2024 | 591.51k | 3.67% |
| LPL Financial LLCas of 31 Mar 2024 | 146.40k | 0.91% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 119.52k | 0.74% |
| Geode Capital Management LLCas of 31 Mar 2024 | 118.16k | 0.73% |
| Squarepoint OPS LLCas of 31 Mar 2024 | 54.34k | 0.34% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 45.20k | 0.28% |
| Bridgeway Capital Management LLCas of 31 Mar 2024 | 33.62k | 0.21% |
| Kestra Advisory Services LLCas of 31 Mar 2024 | 20.99k | 0.13% |
| Montis Financial LLCas of 31 Mar 2024 | 20.96k | 0.13% |
| Simplex Trading LLCas of 31 Mar 2024 | 15.52k | 0.10% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
